MedTrace Logo

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

NCT06331845 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-03-26

No results posted yet for this study

Summary

This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic chemotherapy (SC).

Conditions

  • Metastatic Nasopharyngeal Carcinoma
  • Intermittent Systematic Chemotherapy

Interventions

DRUG

Gemcitabine

1000 mg/m2 on Days 1 and 8

DRUG

Cisplatin

a total of 80-100 mg/m2 for d1-3

DRUG

Paclitaxel protein-bound

260 mg/m2 on Day 1

DRUG

Capecitabine

a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle

DRUG

Tislelizumab

200 mg on Day 1

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2026-05-01
Completion
2028-05-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331845 on ClinicalTrials.gov